



Advances in Plasma Hemostasis

Guest Editors:

Dr. Andrea Caricasole

Kedrion Biopharma S.p.A,
Galliciano, Italy

Dr. Nicole Ziliotto

Department of Pharmacy,
University of Pisa, Pisa, Italy

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

Although the key plasma proteins involved in hemostasis are known, defining the regulation of each constituent molecular event that leads to clot formation remains an active area of ongoing research. At the genetic level, the increasing availability of genomic data provides clear evidence of protein sequence variation in hemostasis-related plasma proteins, which may explain the variability in protein levels/activity found in the population. At the protein level, protein–protein interactions and post-translational modifications of hemostatic proteins are emerging regulatory mechanisms in physiological and pathological roles. On a temporal scale, the hemostatic system changes and evolves throughout time, with age-related changes in the level/activity of hemostasis plasma proteins likely having an impact on inflammatory and age-related diseases.

An improved understanding of coagulation biology is critical to ensuring optimal prevention, diagnosis, and treatment of thrombotic and hemorrhagic diseases and may provide opportunities to develop novel therapeutic approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)